Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193357 | 1.00 | OPRD1 (0.56) | OPRD1OPRM1OPRK1LTA4HCTSD | |
| SCHEMBL29876633 | 0.88 | LTA4H (0.62) | LTA4HCTSD | |
| SCHEMBL38662780 | 0.87 | CTSD (0.58) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL30053179 | 0.85 | OPRD1 (0.68) | OPRD1OPRM1OPRK1LTA4H | |
| SCHEMBL11682257 | 0.84 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11683004 | 0.84 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11683232 | 0.84 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11683013 | 0.84 | OPRD1 (0.69) | OPRD1OPRM1OPRK1 | |
| SCHEMBL18911384 | 0.83 | OPRM1 (0.43) | OPRD1OPRM1OPRK1CTSD | |
| SCHEMBL18911383 | 0.83 | OPRM1 (0.43) | OPRD1OPRM1OPRK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRM1 3352/4885OPRK1 3229/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRM1 3352/4885OPRK1 3229/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRD1 2871/4885OPRM1 1535/4885OPRK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.